|
Volumn 37, Issue 7, 2007, Pages 287-297
|
Pulmonary arterial hypertension of congenital heart diseases: From reversible pulmonary hypertension to Eisenmenger syndrome
|
Author keywords
Congenital heart defects; Eisenmenger syndrome; Hypertension, pulmonary
|
Indexed keywords
ADENOSINE;
ANTIARRHYTHMIC AGENT;
ANTICOAGULANT AGENT;
ANTIINFLAMMATORY AGENT;
ANTITHROMBOCYTIC AGENT;
BERAPROST;
BOSENTAN;
CALCIUM CHANNEL BLOCKING AGENT;
DIGITALIS;
DIURETIC AGENT;
ENDOTHELIN 1;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
ILOPROST;
LIPOXYGENASE INHIBITOR;
NITRIC OXIDE;
PROSTACYCLIN;
SILDENAFIL;
WARFARIN;
CATHETERIZATION;
CLINICAL FEATURE;
CLINICAL TRIAL;
CONGENITAL HEART DISEASE;
DISEASE ASSOCIATION;
DISEASE CLASSIFICATION;
DRUG DOSE INCREASE;
DRUG HALF LIFE;
DRUG MECHANISM;
DRUG WITHDRAWAL;
ECHOCARDIOGRAPHY;
EISENMENGER COMPLEX;
ELECTROCARDIOGRAM;
EXERCISE TEST;
HEART LUNG TRANSPLANTATION;
HIGH RESOLUTION COMPUTER TOMOGRAPHY;
HUMAN;
LUNG HEMODYNAMICS;
LUNG TRANSPLANTATION;
MULTIDETECTOR COMPUTED TOMOGRAPHY;
OXYGEN THERAPY;
PHLEBOTOMY;
PHYSICAL EXAMINATION;
PULMONARY HYPERTENSION;
REVIEW;
RISK FACTOR;
SUDDEN DEATH;
SURVIVAL TIME;
THORAX RADIOGRAPHY;
THREE DIMENSIONAL IMAGING;
|
EID: 34548239220
PISSN: 17385520
EISSN: 17385555
Source Type: Journal
DOI: 10.4070/kcj.2007.37.7.287 Document Type: Review |
Times cited : (6)
|
References (34)
|